Cargando…
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard of care for most patients, and a significant fracti...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279834/ https://www.ncbi.nlm.nih.gov/pubmed/28182141 http://dx.doi.org/10.2147/DDDT.S104869 |